Hikma Pharmaceuticals PLC, headquartered in London, today issued a comprehensive update on its 2025 business outlook, highlighting robust performance in the European region and strategic organisational changes aimed at accelerating product innovation and pipeline delivery. The company confirms its guidance for full-year group revenue growth in the range of 4% to 6% and has tightened its core operating profit forecast to between $730 million and $750 million, reflecting confidence in its operational execution and market positioning. From a manufacturing perspective, Hikma’s global injectables business is performing in line with previously stated expectations, with accelerated activity in contract manufacturing and strong sales momentum from newly launched products. The European and MENA divisions have emerged as key strategic growth drivers, recording particular strength in facility expansion and market share gains, reinforcing Hikma’s leadership in sterile injectables and generics. Notably, the company has begun the phased introduction of Tyzavan™, a patented reformulation of vancomycin in a ready-to-use bag, with expectations for significant sales acceleration through the year-end and into 2026. In addition, Hikma announced the launch of Starjemza® (ustekinumab-hmny), further expanding its Europe biosimilar footprint.

Hikma anticipates 2025 injectables revenue growth in the 7% to 9% range, supported by contract manufacturing advancements and high operating margins (32%–33%). These developments are underpinned by ongoing manufacturing technology upgrades and operational expansion, positioning the company to respond to strong regional demand for high-value injectable pharmaceuticals across both hospital and outpatient segments.

On the organisational front, Hikma has centralised its global R&D function with the goal of maximising pipeline coordination, synergy, and acceleration. Hafrun Fridriksdottir now leads the unified R&D structure, combining leadership of the Hikma Rx business and R&D oversight. The reconfigured group focuses on three strategic product segments: Injectables, Respiratory/Semi-solids & Liquids, and Solid Orals, each supported by dedicated regulatory affairs and R&D operations teams. This reorganisation is designed to streamline the delivery of complex new molecules, speed up high-value product launches, and facilitate greater collaboration across global sites—particularly relevant for European manufacturing hubs and technology centres.

Additionally, Hikma has announced the departure of Dr Bill Larkins, long-time leader of the Injectables business, effective at the end of the year. Group CEO Riad Mishlawi will temporarily assume leadership of the Injectables segment, ensuring business continuity and sustained strategic focus during the transition. The combination of pipeline acceleration, facility upgrades, and global synergy is viewed by Hikma as vital to maintaining its competitive edge in Europe’s rapidly evolving pharmaceutical manufacturing landscape.

For pharmaceutical executives, R&D leads, and manufacturing managers in Europe, Hikma’s updates signal intensified investment into technological and operational advancement, heightened strategic focus on biosimilars and value-added contract manufacturing, and enhanced regulatory alignment. The restructuring of global R&D is expected to unlock broader opportunities for CRO/CMO partnerships, supply chain innovation, and complex product development, especially in the high-growth steriles sector. Procurement and technology vendors are likely to see increased demand for advanced equipment, cleanroom solutions, and automation technologies as Hikma pursues its medium-term growth objectives across the region. Overall, the developments showcase a business-driven approach to pharmaceutical innovation, manufacturing, and strategic organisation, reflecting ongoing commitment to European market leadership and operational excellence in 2025 and beyond.